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In their recently published article, Dr Aberegg and 
colleagues described interesting results of a literature 
search for randomized controlled trials comparing 
mortality of therapies for critically ill adults in ﬁ  ve high 
impact journals over a 10 year period [1]. Th  e authors 
show that the predicted delta (the eﬀ  ect size of a therapy 
compared to control) used for power calculations was 
substantially larger than the observed delta in the 
majority of the included studies. Th   ey conclude that this 
ﬁ   nding, referred to as ‘delta inﬂ   ation’, led to under-
powered trials in the ﬁ  eld of critical care medicine.
We agree that treatment eﬀ  ects are small in this ﬁ  eld of 
medicine and that many critical care trials have been 
underpowered. Th  is problem is particularly relevant to 
the ﬁ  eld of neurocritical care after traumatic brain injury 
[2]. Th  e IMPACT (International Mission on Prognosis 
and Clinical Trial Design in Traumatic Brain Injury) 
Study Group extensively investigated possible causes and 
solutions and recently reported recommendations for 
improving the design and analysis of future clinical trials 
in traumatic brain injury to increase statistical power [3]. 
Th  ese include the use of relatively broad enrolment 
criteria instead of strict patient selection [4], covariate 
adjustment for baseline patient characteristics [5], and 
ordinal rather than dichotomous outcome analysis [6]. In 
our opinion these recommendations are also applicable 
to other ﬁ  elds of critical care research characterized by 
heterogeneous patient populations. We submit that 
adopting these recommendations in future trials will 
increase the chance of detecting small but clinically 
relevant treatment eﬀ  ects in critical care medicine.
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